Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells.

Irofulven (hydroxymethylacylfulvene) is a novel antitumor drug, which acts by alkylating cellular macromolecular targets. The drug is a potent inducer of apoptosis in various types of tumor cells, whereas it is nonapoptotic in normal cells. This study defined molecular responses to irofulven involving mitochondrial dysfunction and leading to death of prostate tumor LNCaP-Pro5 cells. Irofulven caused early (2-5 hours) translocation of the proapoptotic Bax from cytosol to mitochondria followed by the dissipation of mitochondrial membrane potential and cytochrome c release at 4 to 12 hours. These effects preceded caspase activation and during the first 6 hours were not affected by caspase inhibitors. Processing of caspase-9 initiated the caspase cascade at approximately 6 hours and progressed over time. The activation of the caspase cascade provided a positive feedback loop that enhanced Bcl-2-independent translocation and cytochrome c release. General and specific caspase inhibitors abrogated irofulven-induced apoptotic DNA fragmentation with the following order of potency: pan-caspase > or = caspase-9 > caspase-8/6 > caspase-2 > caspase-3/7 > caspase-1/4. Abrogation of caspase-mediated DNA fragmentation failed to salvage irofulven-treated cells from growth inhibition and loss of viability, demonstrating a substantial contribution of a caspase-independent cell death. Monobromobimane, an inhibitor of alternative caspase-independent apoptotic pathway that is mediated by mitochondrial permeability transition, antagonized both apoptosis, measured as phosphatidylserine externalization, and cytotoxicity of irofulven. Collectively, the results indicate that irofulven-induced signaling is integrated at the level of mitochondrial dysfunction. The induction of both caspase-dependent and caspase-independent death pathways is consistent with pleiotropic effects of irofulven, which include targeting of cellular DNA and proteins.

[1]  C. Brenner,et al.  The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death. , 2003, Current medicinal chemistry.

[2]  M. Kelner,et al.  Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft , 2000, Anti-cancer drugs.

[3]  J. Roth,et al.  GSH depletion enhances adenoviral bax-induced apoptosis in lung cancer cells , 2004, Cancer Gene Therapy.

[4]  S. Moolgavkar.  Cancer Models , 2019, Frontiers Research Topics.

[5]  Huiyun Liang,et al.  Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent. , 2003, Biochemical pharmacology.

[6]  Boris Zhivotovsky,et al.  DNA damage-induced apoptosis , 2004, Oncogene.

[7]  P. Vandenabeele,et al.  Mitochondrial intermembrane proteins in cell death. , 2003, Biochemical and biophysical research communications.

[8]  T. Herman,et al.  Targeting Apoptosis by Hydroxymethylacylfulvene in Combination with Gamma Radiation in Prostate Tumor Cells , 2000, Radiation research.

[9]  A. Halestrap,et al.  The permeability transition pore complex: another view. , 2002, Biochimie.

[10]  D. Phillips,et al.  DNA adducts from chemotherapeutic agents. , 1996, Mutation research.

[11]  V. Dawson,et al.  Role of AIF in caspase-dependent and caspase-independent cell death , 2004, Oncogene.

[12]  Emad S. Alnemri,et al.  Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent Manner , 1999, The Journal of cell biology.

[13]  G. Kroemer,et al.  Mitochondrion as a novel target of anticancer chemotherapy. , 2000, Journal of the National Cancer Institute.

[14]  J. Woynarowski,et al.  Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). , 1999, Biochemical pharmacology.

[15]  D. V. Von Hoff,et al.  Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells. , 2001, Anticancer research.

[16]  Y. Ikawa,et al.  Dimerization and Processing of Procaspase-9 by Redox Stress in Mitochondria* , 2004, Journal of Biological Chemistry.

[17]  A. Almasan,et al.  Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis , 2000, Cell Death and Differentiation.

[18]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[19]  N. Trani,et al.  Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan , 2000, Leukemia.

[20]  S. Srinivasula,et al.  Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis , 2001, Oncogene.

[21]  Keisuke Kuida,et al.  Reduced Apoptosis and Cytochrome c–Mediated Caspase Activation in Mice Lacking Caspase 9 , 1998, Cell.

[22]  R. Taetle,et al.  Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. , 1998, European journal of cancer.

[23]  M. Kelner,et al.  Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines , 1999, Cancer Chemotherapy and Pharmacology.

[24]  J. Woynarowski,et al.  Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). , 2000, Biochemical pharmacology.

[25]  M. Kelner,et al.  Preparation and biological activity of amino acid and peptide conjugates of antitumor hydroxymethylacylfulvene. , 2000, Journal of Medicinal Chemistry.

[26]  M. Kelner,et al.  Metabolism of antitumor hydroxymethylacylfulvene by rat liver cytosol. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[27]  S. Weitman,et al.  Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo. , 2004, Anticancer research.

[28]  D. Paustenbach,et al.  Interlaboratory validation of a new assay for DNA-protein crosslinks. , 1996, Mutation research.

[29]  S. Weitman,et al.  Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models , 2004, The Prostate.

[30]  B. Joseph,et al.  Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment , 2002, Oncogene.

[31]  J. Woynarowski,et al.  Preferential targeting of apoptosis in tumor versus normal cells. , 2002, Biochimica et biophysica acta.

[32]  J. Martinou,et al.  Role of mitochondrial membrane permeabilization in apoptosis and cancer , 2004, Oncogene.

[33]  C. Franceschi,et al.  JC‐1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess ΔΨ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis , 1997, FEBS letters.

[34]  R. Kofler,et al.  Mitochondrial membrane sensitivity to depolarization in acute myeloblastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status. , 2001, Blood.

[35]  C. Reutelingsperger,et al.  Flow cytometry of apoptotic cell death. , 2000, Journal of immunological methods.

[36]  G. Kroemer,et al.  Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis , 2000, Oncogene.

[37]  D. Johnson,et al.  Analysis of the role of conserved cysteine residues in the bcl-2 oncoprotein. , 2000, Biochemical and biophysical research communications.

[38]  A. Halestrap,et al.  Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. , 2002, The Biochemical journal.

[39]  Y. Tsujimoto.  Cell death regulation by the Bcl‐2 protein family in the mitochondria , 2003 .

[40]  D. V. Von Hoff,et al.  Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. , 1997, Cancer research.

[41]  J. Prous,et al.  Gateways to clinical trials. March 2003. , 2003, Methods and findings in experimental and clinical pharmacology.

[42]  G. Kroemer,et al.  Apoptosis-inducing factor (AIF): caspase-independent after all , 2004, Cell Death and Differentiation.

[43]  D. Troyer,et al.  Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). , 1997, Biochemical pharmacology.

[44]  T. Kuwana,et al.  Bcl-2-family proteins and the role of mitochondria in apoptosis. , 2003, Current opinion in cell biology.

[45]  T. Hara,et al.  Caspase-dependent cytosolic release of cytochrome c and membrane translocation of Bax in p53-induced apoptosis. , 2001, Experimental cell research.

[46]  G. Kroemer,et al.  The thiol crosslinking agent diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition , 1998, Oncogene.

[47]  K. Tanabe,et al.  Current status of the molecular mechanisms of anticancer drug-induced apoptosis , 2002, Cancer Chemotherapy and Pharmacology.

[48]  E. Raymond,et al.  Phase I population pharmacokinetics of irofulven , 2003, Anti-cancer drugs.

[49]  K. Akuta,et al.  The Number of Platinum Atoms Binding to DNA, RNA and Protein Molecules of HeLa Cells Treated with Cisplatin at Its Mean Lethal Concentration , 1992, Japanese journal of cancer research : Gann.

[50]  Xiang Yu,et al.  NADPH Alkenal/One Oxidoreductase Activity Determines Sensitivity of Cancer Cells to the Chemotherapeutic Alkylating Agent Irofulven , 2004, Clinical Cancer Research.

[51]  Huiyun Liang,et al.  Irofulven Induces Apoptosis in Breast Cancer Cells Regardless of Caspase-3 Status* , 2004, Breast Cancer Research and Treatment.

[52]  G. Gao,et al.  N‐terminal cleavage of Bax by calpain generates a potent proapoptotic 18‐kDa fragment that promotes Bcl‐2‐independent cytochrome C release and apoptotic cell death , 2000, Journal of cellular biochemistry.